EGFR and neoplasm: There is a class of anticancer drugs called EGFR inhibitors, which can specifically inhibit the activity of EGFR or prevent the binding of EGFR to its ligands, thus inhibiting the activation of its downstream signaling pathway and achieving the goal of inhibiting tumor growth.